THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA

Abstract Medulloblastoma (MB) is the most common pediatric brain tumor malignancy, and one of the leading causes of childhood cancer mortality. Often associated with tumor recurrence, relapsed MB patients are limited to palliation outwith the paucity of clinical trials available, carrying a mortality rate approaching 100%. Selectively targeting the MB stem cell population that evade conventional chemoradiotherapy and drive recurrence, can …